# Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

> **NCT07754045** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Lumos Pharma** · enrollment: 202 (estimated)

## Conditions studied

- Obesity & Overweight

## Interventions

- **DRUG:** LUM-201
- **DRUG:** Placebo
- **DRUG:** Semagludtide

## Key facts

- **NCT ID:** NCT07754045
- **Lead sponsor:** Lumos Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-15
- **Primary completion:** 2028-02-15
- **Final completion:** 2028-02-15
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07754045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07754045, "Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07754045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*